TD Cowen Downgrades Repare Therapeutics (NASDAQ:RPTX) to Hold

Repare Therapeutics (NASDAQ:RPTX) was downgraded by equities researchers at TD Cowen from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

A number of other research firms have also commented on RPTX. Cowen lowered shares of Repare Therapeutics to a “hold” rating in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Repare Therapeutics in a research note on Wednesday, October 8th. HC Wainwright decreased their price target on Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Finally, Wall Street Zen upgraded Repare Therapeutics to a “hold” rating in a research report on Saturday. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Repare Therapeutics has an average rating of “Hold” and a consensus price target of $3.50.

Repare Therapeutics Price Performance

Shares of NASDAQ:RPTX opened at $2.23 on Monday. The business’s fifty day moving average price is $1.80 and its two-hundred day moving average price is $1.60. Repare Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $4.07. The stock has a market capitalization of $95.87 million, a price-to-earnings ratio of -1.32 and a beta of 1.06.

Repare Therapeutics (NASDAQ:RPTX) last issued its quarterly earnings data on Friday, November 14th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.43. The company had revenue of $11.62 million for the quarter, compared to the consensus estimate of $7.50 million. Research analysts expect that Repare Therapeutics will post -2.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Quinn Opportunity Partners LLC bought a new position in Repare Therapeutics in the 2nd quarter valued at $56,000. XTX Topco Ltd bought a new stake in shares of Repare Therapeutics during the second quarter worth $60,000. Squarepoint Ops LLC acquired a new position in shares of Repare Therapeutics during the third quarter valued at $115,000. Affinity Asset Advisors LLC boosted its holdings in Repare Therapeutics by 100.0% in the first quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company’s stock valued at $197,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Militia Capital Partners LP bought a new position in Repare Therapeutics in the second quarter valued at about $166,000. Institutional investors own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.